Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma.

L Mas, J Cros, M Svrcek, J L Van Laethem, J F Emile, V Rebours, R Nicolle, J B Bachet

Clinics and research in hepatology and gastroenterology 2023 Apr

filter terms:

Trop-2 is overexpressed in tumor cells of various cancers, including pancreatic ductal adenocarcinoma (PDAC), and has emerged as a potent therapeutic target. We evaluated Trop-2 expression both at the transcriptomic and protein levels, and its correlation with tumor features and patients' outcomes in a large cohort of PDAC. We included patients undergoing pancreatic resection for PDAC in 5 academic hospitals in France and Belgium. Transcriptomic profiles were obtained from FFPE tissue samples, with paired primary -25and metastatic lesions when available. Protein expression was evaluated by immunohistochemistry (IHC) using tissue micro-arrays. 495 patients (male 54%, median age 63 years) were included between 1996 and 2012. Trop-2 mRNA expression was significantly associated to tumor cellularity, but no association with survival nor with any clinical or pathological features was observed, with tumor cells showing an overall high expression among every subgroup. Trop-2 mRNA expression was maintained between primary and metastatic lesion in all 26 paired samples evaluated. In 50 tumors assessed by IHC, 30%, 68% and 2% harbored a high, medium, or low Trop-2 expression score, respectively. Trop-2 staining was significantly associated to mRNA expression, but not to survival or any pathological features. Our results suggest Trop-2 overexpression as a ubiquitous marker of PDAC tumor cells and thus a promising therapeutic target to evaluate in these patients. Copyright © 2023. Published by Elsevier Masson SAS.

Citation

L Mas, J Cros, M Svrcek, J L Van Laethem, J F Emile, V Rebours, R Nicolle, J B Bachet. Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma. Clinics and research in hepatology and gastroenterology. 2023 Apr;47(4):102108